-
Mashup Score: 67
Leukemia – Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
Background Leukemias driven by activated, chimeric FGFR1 kinases typically progress to AML which have poor prognosis. Mouse models of this syndrome allow detailed analysis of cellular and molecular changes occurring during leukemogenesis. We have used these models to determine the effects of leukemia development on the immune cell composition in the leukemia microenvironment during leukemia development and progression. Methods Single cell RNA sequencing (scRNA-Seq) was used to characterize leukemia associated neutrophils and define gene expression changes in these cells during leukemia progression. Results scRNA-Seq revealed six distinct subgroups of neutrophils based on their specific differential gene expression. In response to leukemia development, there is a dramatic increase in only two of the neutrophil subgroups. These two subgroups show specific gene expression signatures consistent with neutrophil precursors which give rise to immature polymorphonuclear myeloid-derived suppres
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2LAST CALL TO SUBMIT YOUR APPLICATION FOR THE 2024 JOHN GOLDMAN RESEARCH AWARD: DEADLINE TOMORROW! - 23 day(s) ago
ESH JOHN GOLDMAN INTERNATIONAL RESEARCH AWARD LAST CHANCE TO SUBMIT YOUR APPLICATION: DEADLINE TOMORROW – April 25 th, 2024 (23:59 CEST) The European School of Haematology (ESH) is proud to announce the 5 th John Goldman Research Award. The recipient of this annual award will receive a total of 80K€ to finance or co-finance a research project with a focus on MRD in CML and Related Diseases. The research project start date will be October 1 st, 2024 and will have a maximum duration of two years. The
Source: mailchi.mpCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 26Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML) - 2 month(s) ago
Olutasidenib, a potent, selective, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, is FDA-approved for relapsed/refractory (R/R) acute myeloid leukemia (AML). Here we report efficacy and…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5The interaction between social determinants of health and cervical cancer survival: A systematic review - PubMed - 2 month(s) ago
There is a deficit in the number of studies comprehensively assessing the impact of SDH on cervical cancer treatment-related outcomes. Marital status, hospital volume and health insurance status are potential predictors of worse outcome.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
We are delighted to announce the recipients of the 2024 iCMLf Prizes; Professor Neil P. Shah (Rowley Prize), Professor Jeff H Lipton (Goldman Prize), and Viji Venkatesh (iCMLf Prize). Following numerous nominations received from the CML community, a panel of previous prize winners and the iCMLf Directors and Advisors has selected these individuals to acknowledge their exceptional contributions to advancing our understanding of CML biology and enhancing CML management. All three are globally respected
Source: mailchi.mpCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 30Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors - 2 month(s) ago
Tyrosine kinase inhibitors (TKIs) are standard therapy for patients with chronic myeloid leukemia. Each of these drugs has a specific profile of tyros…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6LinkedIn - 4 month(s) ago
This link will take you to a page that’s not on LinkedIn
Source: lnkd.inCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5HOME - 28th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma - 4 month(s) ago
OverviewNow in its 28th year, the International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies with the practical tools to translate emerging data into the best therapy for their patients, to personalize care according to patient and tumor characteristics, and to apply novel treatment strategies to…
Source: event.gotoper.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23The interaction between social determinants of health and cervical cancer survival: A systematic review - 5 month(s) ago
This systematic review aimed to investigate what are the most relevant social determinants of health (SDH), how they are measured, how they interact a…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
Now published, asciminib showing high efficacy and tolerability in CML-CP with T315I. Honored to work with such great team of collaborators and friends. @GACancerCenter @jvalentingg @DelphineGJRea @AndreasHochhaus @mjmauroMD @timhughesCML @icmlf https://t.co/qIlbKexmrE